August 15, 2019 / 1:22 PM / 2 months ago

Sanofi scores double win in Federal Circuit on Jevtana patents

A federal appeals court on Wednesday delivered a double dose of good news to Sanofi-Aventis U.S., affirming the validity of its first patent on the prostate-cancer drug Jevtana and overturning a ruling against a later patent on a method of administering it.

The U.S. Court of Appeals for the Federal Circuit said a trial judge in New Jersey had properly rejected “convoluted” arguments against the first patent by Mylan Laboratories, Actavis LLC and several other generic drugmakers that Sanofi had sued for infringement.

To read the full story on Westlaw Practitioner Insights, click here:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below